Biogen Idec, Neurimmune in AD deal

BIIB and Neurimmune (Zurich, Switzerland) partnered to develop and commercialize human antibodies that bind to beta amyloid to treat Alzheimer's disease (AD). Neurimmune will use its Reverse Translati...